LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions

New safety information from post-market use of LEMTRADA has been reported and includes fatal cases, cardiovascular adverse events that have occurred shortly after LEMTRADA infusions, and immune-mediated adverse reactions. The LEMTRADA Canadian Product Monograph has been updated to include a revised indication for use and safety information.

Product safety